Patricia S Steeg

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Clinical-translational approaches to the Nm23-H1 metastasis suppressor
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 14:5006-12. 2008
  2. pmc The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model
    Hui Liu
    Department of Cancer Biology, The University of Texas, MD, Anderson Cancer Center, Houston, TX 77030, USA
    BMC Cancer 12:583. 2012
  3. pmc Metastasis: a therapeutic target for cancer
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 5:206-19. 2008
  4. ncbi Tumor metastasis: mechanistic insights and clinical challenges
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute Building 37, Room 1122, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:895-904. 2006
  5. doi Brain metastases as preventive and therapeutic targets
    Patricia S Steeg
    National Cancer Institute, Bethesda, MD 20892, USA
    Nat Rev Cancer 11:352-63. 2011
  6. pmc New insights into the tumor metastatic process revealed by gene expression profiling
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Pathol 166:1291-4. 2005
  7. ncbi Perspectives on classic article: metastasis suppressor genes
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:E4. 2004
  8. ncbi The gift of absorption
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Researchm National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 3:415-8. 2004
  9. ncbi Metastasis suppressors alter the signal transduction of cancer cells
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 3:55-63. 2003
  10. ncbi Metastasis suppressor genes: basic biology and potential clinical use
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Breast Cancer 4:51-62. 2003

Detail Information

Publications68

  1. pmc Clinical-translational approaches to the Nm23-H1 metastasis suppressor
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 14:5006-12. 2008
    ....
  2. pmc The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model
    Hui Liu
    Department of Cancer Biology, The University of Texas, MD, Anderson Cancer Center, Houston, TX 77030, USA
    BMC Cancer 12:583. 2012
    ..In this study, we show that the targeted knockdown of MMP-1 in breast cancer cells with enhanced brain metastatic ability not only reduced primary tumor growth, but also significantly inhibited brain metastasis...
  3. pmc Metastasis: a therapeutic target for cancer
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 5:206-19. 2008
    ..Here we discuss the similarity and differences between primary tumors and metastases, pathways controlling the colonization of a distant organ, and incorporation of antimetastatic therapies into clinical testing...
  4. ncbi Tumor metastasis: mechanistic insights and clinical challenges
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute Building 37, Room 1122, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:895-904. 2006
  5. doi Brain metastases as preventive and therapeutic targets
    Patricia S Steeg
    National Cancer Institute, Bethesda, MD 20892, USA
    Nat Rev Cancer 11:352-63. 2011
    ..Advances in the chemoprevention of brain metastases, the validation of tumour radiation sensitizers and the amelioration of cognitive deficits caused by whole-brain radiation therapy are discussed...
  6. pmc New insights into the tumor metastatic process revealed by gene expression profiling
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Pathol 166:1291-4. 2005
  7. ncbi Perspectives on classic article: metastasis suppressor genes
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 96:E4. 2004
  8. ncbi The gift of absorption
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Researchm National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 3:415-8. 2004
  9. ncbi Metastasis suppressors alter the signal transduction of cancer cells
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 3:55-63. 2003
    ..So how might we use this knowledge to improve the treatment of patients with cancer?..
  10. ncbi Metastasis suppressor genes: basic biology and potential clinical use
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Breast Cancer 4:51-62. 2003
    ..Clinical testing of agents that increase metastasis-suppressor gene expression is expected to require tailored trial designs...
  11. pmc Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program
    Patricia S Steeg
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:3643-5. 2008
  12. ncbi Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Building 10, Room 2A33, Bethesda, MD 20892, USA
    Cancer Lett 190:1-12. 2003
    ..Other candidate histidine phosphorylated proteins are identified. These data suggest the existence of another series of phosphorylation patterns in signal transduction...
  13. pmc Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain
    Brunilde Gril
    Women s Cancers Section, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 1122, MSC 4254, Bethesda, MD 20892, USA
    J Natl Cancer Inst 100:1092-103. 2008
    ..We examined the efficacy of lapatinib, an inhibitor of the epidermal growth factor receptor (EGFR) and HER2 kinases, for preventing the outgrowth of breast cancer cells in the brain in a mouse xenograft model of brain metastasis...
  14. doi Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks
    Diane Palmieri
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Genetics Branch, National Cancer Institute NIH, Bethesda, Maryland, USA
    Clin Cancer Res 15:6148-57. 2009
    ..We report the pharmacokinetic, efficacy, and mechanism of action studies for the histone deactylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in a preclinical model of brain metastasis of triple-negative breast cancer...
  15. pmc Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells
    Brunilde Gril
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Am J Pathol 182:2368-79. 2013
    ....
  16. ncbi Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer
    Diane Palmieri
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Natl Cancer Inst 97:632-42. 2005
    ..Here, we tested whether MPA treatment inhibits metastatic colonization of a hormone receptor-negative breast cancer cell line in vivo...
  17. ncbi Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of Ras via a histidine protein kinase pathway
    Melanie T Hartsough
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 277:32389-99. 2002
    ..The data identify a complex in vitro histidine-to-serine protein kinase pathway, which may contribute to signal transduction and metastasis...
  18. pmc Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts
    Andrew Baschnagel
    Radiation Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Mol Cancer Ther 8:1589-95. 2009
    ..There was a greater than additive improvement in survival in our intracranial model. Combining vorinostat with radiation may be a potential treatment option for patients with breast cancer who develop brain metastases...
  19. ncbi TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells
    Daniel P Fitzgerald
    Women s Cancers Section, Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland, USA
    Mol Cancer Ther 11:1959-67. 2012
    ..When TPI-287 treatment was delayed until days 18, 22, and 26 postinjection, efficacy was reduced (17% reduction, not significant). These data suggest that TPI-287 may have efficacy when administered early in the course of the disease...
  20. ncbi Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2
    Christine E Horak
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 67:11751-9. 2007
    ..73; P = 0.004). The data indicate that Nm23-H1 down-regulation of EDG2 is functionally important to suppression of tumor metastasis...
  21. pmc The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models
    Brunilde Gril
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 6:e25625. 2011
    ..In conclusion, using pazopanib, tumor B-Raf status was identified as a significant determinant of both tumor growth and angiogenesis...
  22. pmc Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis
    Diane Palmieri
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 7322, USA
    Mol Cancer Res 7:1438-45. 2009
    ..028). The data suggest that HK2 overexpression is associated with metastasis to the brain in breast cancer and it may be a therapeutic target...
  23. ncbi Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2
    Christine E Horak
    Women s Cancer Section, Laboratory of Molecular Pharmacology, National Cancer Institute NIH, 37 Convent Drive, Bethesda, MD 20892, USA
    Cancer Res 67:7238-46. 2007
    ..These data suggest that Nm23-H1 suppresses metastasis, at least in part, through down-regulation of EDG2 expression...
  24. ncbi Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds
    Taoufik Ouatas
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:3763-72. 2003
    ..We searched for well-tolerated compounds that could elevate Nm23 metastasis suppressor expression in metastatic human breast cancer cell lines...
  25. ncbi Translational approaches using metastasis suppressor genes
    Diane Palmieri
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Building 37, Room 1122, NIH, Bethesda, MD 20892, USA
    J Bioenerg Biomembr 38:151-61. 2006
    ..To date, medroxyprogesterone acetate (MPA) has been identified as a candidate compound for clinical testing...
  26. pmc Nm23-h1 binds to gelsolin and inactivates its actin-severing capacity to promote tumor cell motility and metastasis
    Natascia Marino
    Authors Affiliations Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda and Laboratory of Proteomics and Analytical Technologies, Science Applications International Corporation Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland
    Cancer Res 73:5949-62. 2013
    ..We observed no variation in proliferation among lung metastases. Our findings suggest a new actin-based mechanism that can suppress tumor metastasis...
  27. pmc SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases
    Siyuan Zhang
    Authors Affiliations Departments of Molecular and Cellular Oncology, Neurosurgery, and Pathology, The University of Texas MD Anderson Cancer Center Cancer Biology Program, Graduate School of Biomedical Sciences Houston, Houston, Texas Women s Cancers Section, Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland and Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana
    Cancer Res 73:5764-74. 2013
    ..Our results provide a rationale for clinical evaluation of Src-targeting regimens to treat patients with breast cancer suffering from brain metastasis...
  28. pmc Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization
    Daniel P Fitzgerald
    Women s Cancers Section, Laboratory of Molecular Pharmacology, National Cancer Institute, Building 37, Room 1126, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Exp Metastasis 25:799-810. 2008
    ..001), suggesting that brain tissue secretes factors conducive to tumor cell growth. Molecules used to signal between tumor cells and the surrounding glia could provide a new avenue of therapeutic targets for brain metastases...
  29. ncbi Inhibition of signal transduction by the nm23 metastasis suppressor: possible mechanisms
    Massimiliano Salerno
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Exp Metastasis 20:3-10. 2003
    ..We hypothesize that the mechanism of action of Nm23 in metastasis suppression involves diminished signal transduction downstream of a particular receptor. Candidate biochemical mechanisms are identified and discussed herein...
  30. pmc Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells
    Massimiliano Salerno
    Women s Cancers Section, Laboratory of Pathology, Building 10, Room 2A33, National Cancer Institute, Bethesda, MD 20892, USA
    Mol Cell Biol 25:1379-88. 2005
    ..Metastasis suppressor expression levels can impact traditional signaling pathways, such as the Erk pathway, resulting in altered tumor cell sensitivity to cancer therapeutics...
  31. ncbi Basic and translational advances in cancer metastasis: Nm23
    Taoufik Ouatas
    Women s Cancers Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Bioenerg Biomembr 35:73-9. 2003
    ..This review also discusses therapeutic options on the basis of reexpression of metastasis suppressors...
  32. pmc Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer
    Jean Claude A Marshall
    The Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    J Natl Cancer Inst 104:1306-19. 2012
    ..However, the effects of LPA1 inhibition on primary tumor size, metastasis, and metastatic dormancy have not been investigated...
  33. ncbi Brain metastases of breast cancer
    Diane Palmieri
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Breast Dis 26:139-47. 2006
    ..New therapies with permeability for the blood-brain barrier are needed to counteract both types of tumor cells...
  34. pmc Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility
    Jong Heun Lee
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Res 68:639-44. 2008
    ..The data also show that changes in mRNA splicing patterns accompany metastatic progression, which may contribute to proteome instability...
  35. pmc Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis
    Brunilde Gril
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:142-53. 2011
    ..We have tested pazopanib, a recently approved antiangiogenic drug that targets VEGFR1, VEGFR2, VEGFR3, PDGFRβ, PDGFRα, and c-kit, for prevention of experimental brain metastases and mechanism of action...
  36. ncbi Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain
    Diane Palmieri
    Laboratory of Molecular Pharmacology, Women s Cancers Section, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 67:4190-8. 2007
    ..001). Our data indicate that Her-2 overexpression increases the outgrowth of metastatic tumor cells in the brain in this model system...
  37. ncbi Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells
    Diane Palmieri
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD 20874, USA
    Breast Cancer Res Treat 100:127-37. 2006
    ..The data provide a first demonstration that Rab11a modulates EGFR recycling, and promotes the proliferation but inhibits the motility of an immortal breast line, consistent with the DCIS phenotype...
  38. pmc Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression
    Jean Claude Marshall
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Mol Cell Biochem 329:115-20. 2009
    ..A Phase II clinical trial of high dose MPA, alone or in combination with metronomic chemotherapy has recently opened...
  39. pmc Altered gene and protein expression by Nm23-H1 in metastasis suppression
    Jong Heun Lee
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 1122, Bethesda, MD 20892, USA
    Mol Cell Biochem 329:141-8. 2009
    ..The contribution of alternative mRNA splicing to cancer and cancer metastasis is poorly defined. It is possible that Nm23-H1, through the regulation of RNA processing proteins, may play a role in proteome stability...
  40. doi Quantitative protein network monitoring in response to DNA damage
    Satoshi Nishizuka
    Molecular Therapeutics Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Proteome Res 7:803-8. 2008
    ..Although the present study focuses on the DNA damage-repair pathway, the technique is generally useful to the study of protein signaling...
  41. ncbi Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth
    William G McDermott
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NCI NIH, 37 Convent Dr, Bethesda, MD 20892, USA
    Clin Exp Metastasis 25:131-8. 2008
    ..Similarly, sequence differences between DR-Nm23 and its homologs may be important for anchorage independent growth suppression...
  42. pmc Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies
    Brunilde Gril
    Women s Cancers Section, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    Eur J Cancer 46:1204-10. 2010
    ..Recent findings on the biology of this disease and translational leads identified by molecular studies are discussed in this article...
  43. ncbi Proteomic approaches to the diagnosis, treatment, and monitoring of cancer
    Julia D Wulfkuhle
    FDA NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Adv Exp Med Biol 532:59-68. 2003
    ....
  44. ncbi MMTV-associated transcription factor binding sites increase nm23-H1 metastasis suppressor gene expression in human breast carcinoma cell lines
    Taoufik Ouatas
    Women s Cancers Section, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Exp Metastasis 19:35-42. 2002
    ..Our data identify a complex regulatory pattern for nm23-H1 transcription, and suggest that a mammary-specific cassette of transcription factors contribute to its elevated expression..
  45. pmc Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage
    Daniel P Fitzgerald
    Women s Cancer s Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    Cancer Res 72:144-53. 2012
    ..Our findings establish PEDF as both a metastatic suppressor and a neuroprotectant in the brain, highlighting its role as a double agent in limiting brain metastasis and its local consequences...
  46. doi Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene
    Natascia Marino
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 1122, Bethesda, MD 20892, USA
    Cancer Metastasis Rev 31:593-603. 2012
    ..Recently, based on the inverse correlation of Nm23 and LPA1 expression, a LPA1 inhibitor has been shown to both inhibit metastasis and induce metastatic dormancy...
  47. ncbi c-Met ectodomain shedding rate correlates with malignant potential
    Gagani Athauda
    Urologic Oncology Branch, Laboratory of Molecular Pharmacology, and Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1107, USA
    Clin Cancer Res 12:4154-62. 2006
    ..We hypothesized that c-Met overexpression in cancer might result in increased ectodomain shedding, and that its measure could be a useful biomarker of tumor progression...
  48. pmc Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Eur J Cancer 46:340-7. 2010
    ....
  49. pmc The role of metastasis suppressor genes in metastatic dormancy
    Christine E Horak
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    APMIS 116:586-601. 2008
    ..Therapeutic approaches that either mimic the effects of MSGs or re-establish MSG expression in metastatic lesions may hold promise for the establishment or maintenance of dormancy...
  50. ncbi CNS metastases in breast cancer: old challenge, new frontiers
    Nancy U Lin
    Authors Affiliations Dana Farber Cancer Institute, Boston, Massachusetts Medical Oncology Branch, Center for Cancer Research, National Cancer Institute Women s Cancers Section, Laboratory of Molecular Pharmacology and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
    Clin Cancer Res 19:6404-18. 2013
    ..Challenges in current trial design and endpoints are reviewed. Finally, we discuss promising new directions, including novel trial designs, correlative imaging techniques, and enhanced translational opportunities...
  51. pmc Breast cancer metastasis: issues for the personalization of its prevention and treatment
    Natascia Marino
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Electronic address
    Am J Pathol 183:1084-95. 2013
    ..Finally, to maximize the information that can be obtained, increased attention to clinical trial design in the metastasis preventive setting is needed. ..
  52. ncbi Metastasis gets site specific
    Christine E Horak
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Building 37, Room 1122, Bethesda, Maryland 20892, USA
    Cancer Cell 8:93-5. 2005
    ....
  53. ncbi Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models
    Lyuba Varticovski
    Center for Cancer Research, National Cancer Institute, Frederick, Maryland
    Clin Cancer Res 13:2168-77. 2007
    ..Here, we describe and validate a transplantation strategy that circumvents some of these difficulties...
  54. ncbi Quantitative assessment of the p53-Mdm2 feedback loop using protein lysate microarrays
    Sundhar Ramalingam
    Molecular Therapeutics Program, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 67:6247-52. 2007
    ..Based on experimental observations, we determined model parameters and generated an in silico "knockout," reflecting the experimental data, including phosphorylated proteins...
  55. ncbi The biology of metastasis to a sanctuary site
    Diane Palmieri
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 13:1656-62. 2007
    ..Specific, new approaches to combat brain metastatic disease are needed...
  56. doi Protein-protein interactions: a mechanism regulating the anti-metastatic properties of Nm23-H1
    Natascia Marino
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Naunyn Schmiedebergs Arch Pharmacol 384:351-62. 2011
    ..Cumulatively, the data suggest that part of the anti-metastatic function of Nm23-H1 lies in pathways that it interrupts via binding and inactivation of proteins...
  57. ncbi Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo
    Joell J Gills
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 13:5183-94. 2007
    ..Because these drugs cause toxicities that can be associated with inhibition of Akt, an emerging target in cancer, we assessed the potential of HIV protease inhibitors as anticancer agents...
  58. ncbi Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines
    Natascia Marino
    Women s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 37 Room 1126, 37 Convent Drive, Bethesda, MD, 20892, USA
    Clin Exp Metastasis . 2014
    ..045 and p = 0.009 respectively). This study demonstrates that previously unrecognized genes are inversely related to the expression of multiple MSGs, contribute to aspects of metastasis, and may stand as novel therapeutic targets...
  59. ncbi Combined breast ductal lavage and ductal endoscopy for the evaluation of the high-risk breast: a feasibility study
    David N Danforth
    Surgery Branch, The Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Surg Oncol 94:555-64. 2006
    ....
  60. doi In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide
    Whoon Jong Kil
    Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:931-8. 2008
    ....
  61. ncbi Proteomics of human breast ductal carcinoma in situ
    Julia D Wulfkuhle
    Women s Cancers Section, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 62:6740-9. 2002
    ..Proteomic analysis of DCIS revealed differential expression patterns distinct from previous nucleic acid-based studies and identified new facets of the earliest stage of breast cancer progression...
  62. pmc A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice
    Cody J Peer
    Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Bethesda, MD, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 927:142-6. 2013
    ..A liquid-liquid extraction procedure was able to recover ∼90% of drug from a small volume (50μL) of mouse plasma. This method was successfully applied to a pharmacokinetic study in mice intravenously injected with DZNep...
  63. ncbi Cancer: micromanagement of metastasis
    Patricia S Steeg
    Nature 449:671-3. 2007
  64. ncbi Angiogenesis inhibitors: motivators of metastasis?
    Patricia S Steeg
    Nat Med 9:822-3. 2003
  65. pmc Breast cancer metastasis to the central nervous system
    Robert J Weil
    Brain Tumor Institute, ND4 40 Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Am J Pathol 167:913-20. 2005
    ..Using such model systems, as well as in vitro analogs of blood-brain barrier penetration and tissue-based studies, new molecular leads into this disease are unfolding...
  66. ncbi In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain
    Chris Heyn
    Imaging Research Laboratories, Robarts Research Institute, London, Ontario, Canada
    Magn Reson Med 56:1001-10. 2006
    ....
  67. ncbi Cancer biology: emissaries set up new sites
    Patricia S Steeg
    Nature 438:750-1. 2005
  68. ncbi Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications
    Richard L Cysyk
    Laboratory of Clinical Pharmacology, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Chem Res Toxicol 19:376-81. 2006
    ..Moreover, reactions with thiol groups of critical cellular proteins could be important to the mechanism of toxicity with this class of anticancer agents...